New oral treatment for severe acne using selective CYP26 inhibitors.
Official title: Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
Funded at Dermaxon, LLC · NIH-10822482 · Data updated 2026-11-12
This study is testing a new pill that aims to help people with severe acne by blocking certain enzymes that break down a skin-friendly vitamin, hoping to improve acne without the usual side effects of current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dermaxon, LLC NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $295,423 |
| NIH project number | 1R43AR083781-01 |
| Project ID | NIH-10822482 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from severe recalcitrant acne who have not responded well to existing treatments.
✕Less likely to help
Patients with mild acne or those who have not been diagnosed with recalcitrant acne may not benefit from this research.
What this research studies
This research aims to develop a new oral medication that selectively inhibits CYP26 enzymes, which are responsible for breaking down retinoic acid in the skin. By targeting these enzymes, the treatment seeks to provide an effective solution for patients suffering from severe recalcitrant acne while minimizing the adverse effects commonly associated with existing retinoid therapies. The approach focuses on creating a safer alternative that avoids the systemic side effects linked to traditional treatments. Patients can expect a potential improvement in their acne condition without the discomfort of typical retinoid side effects.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective oral treatment option for patients with severe acne.
How similar studies have gone: While there have been studies on retinoids, this specific approach using selective CYP26 inhibitors is novel and has not been extensively tested before.
Where this research is happening
-
Dermaxon, LLC
Missoula, United States Active
Researchers
- Principal investigator: Diaz, Philippe J — Dermaxon, LLC
- Study coordinator: Diaz, Philippe J
Related research
Other NIH-funded projects on the same topics.
-
Acne: how skin oils, bacteria, and the immune system interact
A UC system grant is exploring how acne develops by looking at skin oils, skin bacteria, and the body’s immune response to help find new ways to prevent or treat acne.
-
Acne: how skin bacteria, fats, and immunity drive lesions
A large NIH-funded effort at UCLA/UCSD is studying how skin bacteria, fat metabolism, and the immune system interact to cause acne, with plans to translate findings into better treatments.
-
Spironolactone vs doxycycline for acne in women
A multi-center trial compares spironolactone and doxycycline to treat acne in adult women to find which works better with fewer side effects.
-
Novel endolysins to target Cutibacterium acnes for acne treatment
A small research grant is developing a highly specific enzyme therapy to kill the acne-causing bacteria without disturbing good skin or gut bacteria.
-
Th17 extracellular traps and skin bacteria in acne health
A study in people with acne aims to understand how specific skin bacteria and immune cells interact to fight acne-causing germs and how this could lead to better treatments.
-
New bacteria-targeting enzymes to fight acne
Developing species-specific enzymes to remove the acne-causing bacterium Cutibacterium acnes for people with acne.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.